Skip to main content
. 2022 Mar 24;44(4):1463–1471. doi: 10.3390/cimb44040098

Figure 2.

Figure 2

Anti-BCMA CAR-T cell treatment. CAR-T cells target the BCMA protein present on the surface of the myeloma cells and release cytokines, perforines, and granzymes. BCMA shedding is partially dependent on ligand binding and receptor interactions. sBCMA may act as a decoy blocking the CAR-TCR; thus, leading to reduced efficacy of anti-BCMA-CAR-T therapy.